Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

COAST-X Top-Line Results: Ixekizumab Improves Nonradiographic AxSpA VS. Placebo

Key clinical point: Ixekizumab significantly improved the signs and symptoms of nonradiographic axial spondyloarthritis versus placebo.

Major finding: A 40% improvement in Assessment of Spondyloarthritis International Society response criteria was reached at week 16 by 19% of placebo patients and by 35% and 40% of the 2- and 4-week ixekizumab-group patients, and at week 52 by 13%, 30%, and 31% of the patients in the groups, respectively.

Study details: The randomized, placebo-controlled, phase 3 COAST-X trial of 303 patients.

Disclosures: COAST-X was sponsored by Eli Lilly. Dr. Deodhar and most coauthors reported receiving research grants and/or honoraria for consulting or speaking from Eli Lilly and other pharmaceutical companies. Four authors are current employees and shareholders of Eli Lilly.

Citation:

Deodhar A et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 2729.